小儿肺炎支原体感染耐药情况回顾分析

doi:10.11852/zgetbjzz2017-25-09-26

中国儿童保健杂志 ›› 2017, Vol. 25 ›› Issue (9): 951-950.DOI: 10.11852/zgetbjzz2017-25-09-26

小儿肺炎支原体感染耐药情况回顾分析

付晓燕,秦选光,辛德莉

首都医科大学附属北京朝阳医院,北京 100020

收稿日期:2017-03-08 发布日期:2017-09-10 出版日期:2017-09-10
通讯作者: 秦选光,E-mail:qinxuanguang@sina.com
作者简介:付晓燕(1982-),女,辽宁人,医师,硕士研究生,主要研究方向为儿童呼吸系统疾病
基金资助:
北京市科学技术委员会资助项目(Z131100004013029);首都医科大学附属北京友谊医院院级课题(BJYYYY2011-31)

Retrospective analysis of drug resistance of mycoplasma pneumoniae infection in children

FU Xiao-yan,QIN Xuan-guang,XIN De-li

Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China

Received:2017-03-08 Online:2017-09-10 Published:2017-09-10
Contact: QIN Xuan-guang,E-mail:qinxuanguang@sina.com

摘要/Abstract

摘要： 目的了解2015-2016年北京地区儿童肺炎支原体(MP)耐药情况及耐药机制分析。方法采集2015-2016年首都医科大学附属北京朝阳医院儿科收治的,具有发热、咳嗽或咽痛等呼吸道感染症状之一的,门诊和住院的89例患儿的呼吸道咽拭子标本,进行MP 培养与药敏试验,采用巢式PCR扩增法鉴定MP 耐药位点。结果 53例MP阳性,感染率为59%,18株为敏感株,耐药率66%,32株存在23S rRNA 结构域Ⅴ区A2063G 点突变。3株2063、2064位点均有突变。结论北京地区肺炎支原体感染率高,对大环内酯类抗生素耐药率上升趋势,耐药机制主要为23S rRNA 结构域Ⅴ区点突变。

关键词: 肺炎支原体, 耐药, 大环内酯类, 耐药机制

Abstract: Objective To investigate the prevalence and mecharism of drug resistance of mycoplasma pneumoniae (MP) of children in Beijing area in 2015-2016.Method A total of 89 respiratory throat swab specimens were collected from children with fever,cough or sore throat and other respiratory tract infection symptoms,admitted in Beijing Chaoyang Hospital Affiliated to Capital Medical University in 2015-2016.These cases were assayed mycoplasma culture and drug sensitivity test and were amplified by nested PCR method for identification of MP resistance loci.Results 53 cases were positive of mycoplasma pneumonia,with infection rate of 59%.18 cases were sensitive strains and drug resistance rate was 66%.32 strains showed A2063G point mutation in 23S rRNA domain V district.Both A2063G and A2064G point mutation existed in 3 cases.Conclusions Mycoplasma pneumoniae infection rate in Beijing area is prevalent.The macrolide resistance rate is rising and the main resistance mechanism is 23S rRNA domain V point mutation.

Key words: mycoplasma pneumonia, drug resistance, macrolides, resistant mechanism

中图分类号:

R179

付晓燕,秦选光,辛德莉. 小儿肺炎支原体感染耐药情况回顾分析[J]. 中国儿童保健杂志, 2017, 25(9): 951-950.

FU Xiao-yan,QIN Xuan-guang,XIN De-li. Retrospective analysis of drug resistance of mycoplasma pneumoniae infection in children[J]. journal1, 2017, 25(9): 951-950.

参考文献

[1] 殷勇,陆权,闫晓莉,等.肺炎支原体感染的流行病学[J].中华儿科杂志,2016,54(2):91-93.
[2] Liu Y,Ye X,Zhang H,et al.Antimicrobial susceptibility of mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai,China [J].Antimicrob Agents Chemother,2009,53(5):2160-2162.
[3] Xin D,Mi Z,Han X,et al.Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China [J].Antimicrob Agents Chemother,2009,53(5):2158-2159.
[4] Zhou Z,Li X,Chen X,et al.Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang,China [J].Antimicrob Agents Chemother,2015,59(2):1048-1051.
[5] Miyashita N,Oka M,Atypical Pathogen Study Group,et al.Macrolide-resistant mycoplasma pneumoniae in adults with community-acquired pneumonia[J].Int J Antimicrob Agents,2010,36(4):384-385.
[6] Kawai Y,Miyashita N,Yamaguchi T,et al.Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant mycoplasma pneumoniae pneumonia in paediatric patients[J].Respiratory,2012,17(2):354-362.
[7] Dumke R,von Baum H,Lück PC,et al.Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany[J].Clin Microbiol Infect,2010,16(6):613-616.
[8] Peuchant O,Ménard A,Renaudin H,et al.Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis[J].J Antimicrob Chemother,2009,64(1):52-58.
[9] Zheng X,Lee S,Selvarangan R,et al.Macrolide-resistant mycoplasma pneumoniae,United States[J].Emerg Infect Dis,2015,21(8):1470-1472.
[10] Eshaghi A,Memari N,Tang P,et al.Macrolide-resistant mycoplasma pneumoniae in humans,Ontario,Canada,2010-2011[J].Emerg Infect Dis,2013,19(9):1525-1527.
[11] Bébéar CM,Pereyre S.Mechanisms of drug resistance in Mycoplasma pneumoniae [J].Curr Drug Targets Infect Disord,2005,5(3):263-271.
[12] Waites KB,Duffy LB,Bbar CM,et al.Standardized methods andquality control limits for agar and broth microdilution susceptibility testingof mycoplasma pneumoniae,Mycoplasma hominis,and Ureaplaurealyticum[J].J ClinMicrobiol,2012,50(11):3542-3547.
[13] Akaike H,Miyashita N,Kubo M,et al.In vitro activities of 11 antimicrobialagents against macrolide-resistant mycoplasma pneumoniaeisolatesfrom pediatric patients:results from a multicenter surveillancestudy[J].Jpn J Infect Dis,2012,65(6):535-538.
[14] 刘禧杰,辛德莉,李靖,等,肺炎支原体对大环内酯类抗生素的耐药分子机制[J].实用儿科临床杂志,2008,23 (22):1730-1733.
[15] 辛德莉,靡祖煌,韩旭,等,应用巢式聚合酶链反应和测序检测肺炎支原体23S rRNA 中点突变[J].中华儿科杂志,2008,46(7):522-525.
[16] 李靖,崔菲菲,辛德莉,等.儿童呼吸道肺炎支原体感染耐药现状[J].实用儿科临床杂志,2009,24(22):1717-1719.
[17] Xin D,Mi Z,Han X,et al.Molecular mechanisms of macrolide resistance in clinical isolates of mycoplasma pneumoniae from China[J].Antimicmb Agents Chemother,2009,53(5):2158-2159.
[18] Liu Y,Ye X,Zhang H,et al.Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis on macrolide-resisant strains from Shanghai China[J].Antimicrobial Agents and Chemotherapy,2009,53(5):2160-2163.
[19] 韩晓华,路素坤,李书秀,等.肺炎支原体23SrRNA基因突变及其所致肺炎的临床分析[J].中国医科大学学报,2011,40(2):162-165.
[22] 李静宜,孙岚,秦选光,等.实时定量PCR检测肺炎支原体2063位点点突变的方法学研究[J].中国全科医学,2013,16 (11):3774-3777.

小儿肺炎支原体感染耐药情况回顾分析

Retrospective analysis of drug resistance of mycoplasma pneumoniae infection in children

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	朱美君, 季菊花, 朱洁, 宋磊, 周峰, 赵金华. 儿童耐药肺炎支原体DNA载量与23sRNA基因2063位点突变的相关性分析[J]. 中国儿童保健杂志, 2021, 29(9): 1017-1020.
[2]	李九英, 李平真, 邱亚明. IL-33/ST2在肺炎支原体肺炎患儿外周血中的表达研究[J]. 中国儿童保健杂志, 2021, 29(3): 332-334.
[3]	胡春霞, 孔令军, 缪鑫霞, 吴建刚. 儿童哮喘血清胱抑素C和体液免疫功能指标变化及其与肺炎支原体感染的相关性研究[J]. 中国儿童保健杂志, 2021, 29(12): 1347-1350.
[4]	盛江吟, 阮桂英, 尹燕丹, 洪燕, 苏群燕, 南向珍. 儿童肺炎支原体肺炎并发气管炎性狭窄的危险因素及预后[J]. 中国儿童保健杂志, 2020, 28(12): 1385-1388.
[5]	申秋燕, 刘静, 肖夏夏, 王海立, 曹颜辉, 郭晓杰, 李志勇. T淋巴细胞亚群在肺炎支原体感染伴喘息患儿的水平及预后意义[J]. 中国儿童保健杂志, 2019, 27(9): 1012-1014.
[6]	毛璐易, 王宇清. 肺炎支原体肺炎住院患儿混合感染的临床研究及危险因素分析[J]. 中国儿童保健杂志, 2019, 27(8): 917-919.
[7]	苏乐, 梅玲华, 贺巧峰. 肺炎支原体肺炎患儿血清维生素D水平与肺外脏器受累的相关性研究[J]. 中国儿童保健杂志, 2019, 27(7): 782-785.
[8]	李芹,王亚坤,田利远,张曼,王艳艳,李清涛,常海霞. 髓鞘碱性蛋白、神经元特异性烯醇化酶在支原体肺炎并发脑炎患儿中的临床研究[J]. 中国儿童保健杂志, 2019, 27(2): 202-204.
[9]	谢朝云, 熊芸, 覃家露, 杨忠玲, 胡阳. 儿童细菌性重症肺炎多重耐药菌感染相关因素分析[J]. 中国儿童保健杂志, 2018, 26(3): 325-328.
[10]	余静,张慧. 小儿肺炎支原体感染的免疫学研究进展[J]. 中国儿童保健杂志, 2018, 26(11): 1214-1216.
[11]	刘金, 闫虹, 陈小庚, 程菲. 儿童血清维生素A、D、E水平与肺炎支原体肺炎相关性的临床研究[J]. 中国儿童保健杂志, 2018, 26(1): 97-99.
[12]	赵琳,曹丽云,赵梦茹,刘旭,吕高洁,李明盼. 昆明地区2011-2015年小儿下呼吸道肺炎支原体感染情况分析[J]. 中国儿童保健杂志, 2017, 25(9): 957-956.
[13]	肖曙芳,李斌,苏敏,杜廷义,李杨方. 小儿急性下呼吸道感染细菌病原及耐药性九年变迁[J]. 中国儿童保健杂志, 2017, 25(9): 962-961.
[14]	白波,陈波,李广洪,王艳萍,黄惠仪,罗惠玲. 新生儿重症监护病房革兰阴性杆菌分布及耐药性分析[J]. 中国儿童保健杂志, 2017, 25(2): 187-190.
[15]	周彩丽,刘宗伟,周清霞,段全纪. 肺炎支原体对支气管哮喘患儿肺功能的影响[J]. 中国儿童保健杂志, 2016, 24(7): 762-764.